Caremo Recognized as Nanjing Gazelle Enterprise

Recently, the Nanjing Macroeconomic Research Center officially released the 2025 Nanjing Unicorn, Potential Unicorn, and Gazelle Enterprises List, with Caremo securing a spot as a Gazelle Enterprise. This prestigious recognition underscores Caremo’s rapid growth trajectory and immense development potential.

Gazelle Enterprises, renowned for their explosive growth akin to leaping antelopes, lead industry advancements through innovative technologies, forward-looking market insights, and efficient operations. Characterized by strong innovation capabilities, accelerated expansion, cutting-edge specialization, and significant market potential, these enterprises have become vital engines driving high-quality urban economic development.

As a CRO dedicated to delivering integrated drug development services, Caremo consistently integrates technological innovation with industrial collaboration. By accelerating technological upgrades and enhancing R&D efficiency and precision, the company continues to achieve breakthroughs in advanced complex formulation development. To date, Caremo has earned numerous certifications and honors, including:

·National High-Tech Enterprise

· Technology-based SME

·Jiangsu Provincial Private Technology Enterprise

·Jiangsu Potential Unicorn Enterprise

·Nanjing Local Transdermal Drug Delivery Engineering Research Center

·Nanjing Special Dosage Form Drug Engineering Technology Research Center

·Nanjing Postdoctoral Innovation Practice Base

·Top 20 China Pharmaceutical CRO Enterprises

·China's Most Competitive Pharmaceutical Service Enterprise

Caremo’s success stems from its innovative spirit and Nanjing’s thriving industrial ecosystem. Moving forward, the company will maintain its “gazelle-speed” momentum, prioritizing innovative drug R&D technology to fulfill its mission—“Born for Health, Empowered by Innovation”—and contribute greater “Caremo Power” to advance the biopharmaceutical industry.